Glioblastoma multiforme: A bigger challenge in resource-limited countries

References

1. Fine H. A., Dear K. B., Loeffler J. S., Black P. M., Canellos G. P., . Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585-97.

   [Google Scholar]
2. Stupp R, Dietrich P. Y., Kraljevic S. O., Pica A, Maillard I, Maeder P, et al . Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20:1375-82.

   [Google Scholar]
3. Hegi M. E., Diserens A. C., Gorlia T, Hamou M. F., de Tribolet N, Weller M, et al . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.

   [Google Scholar]
4. Krex D, Klink B, Hartmann C, et al . Long-term survival with glioblastoma multiforme. Brain. 2007;130:2596-606.

   [Google Scholar]
5. Kumar N, Kumar P, Angurana S. L., et al . Evalutaion of outcome and prognostic factors in patients with glioblastoma multiforme: A single institution expereicne. J Neurosci Rural Pract. 2013;4:s46-55. suppl 1

   [Google Scholar]
6. Malmström A, Grønberg B. H., Marosi C, Stupp R, Frappaz D, Schultz H, et al . Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized, phase 3 trial. Lancet Oncol. 2012;13:916-26.

   [Google Scholar]
7. Lo S. S., Chang E. L., . Hypofractionated radiation therapy for glioblastoma: Educational ook manuscript. Am Soc Clin Oncol

   [Google Scholar]